The integration of PET-PSMA imaging into prostate cancer management significantly impacts treatment decision-making by facilitating personalized approaches tailored to disease severity and aggressiveness, ultimately leading to more precise and effective management of prostate cancer across different clinical stages. This evidence concerns the gene FOLH1 and prostate cancer.